The success of Sildenafil initially drove a surge for the drug industry, but recent changes present a murky outlook for investors. Generic versions are reducing profits, and continued patent challenges add more https://nanabcxy306520.mpeblog.com/74347918/the-blue-pill-and-big-pharma-a-risky-investment